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Intra-aortic  balloon  counterpulsation  (IABP)  has  been  used  in  various  cardiovascular  conditions  including
cardiogenic  shock.  Prophylactic  systemic  heparinization  has  been  commonly  utilized  to  prevent  throm-
botic  complications.  There  are  a number  of  anticoagulants  in  addition  to heparin;  however,  there  is little
consensus  and  few  data  to support  the  safety  of  alternative  anticoagulation  during  IABP  management.
We  report  here  on  the  case  of a 47-year-old  woman  with  cardiogenic  shock.  She  had  a  medical  historyardiogenic shock
ntra-aortic  balloon counterpulsation
eparin
eparin-induced  thrombocytopenia
rgatroban
of  heparin-induced  thrombocytopenia  (HIT)  type  II  and  soon  after  admission  she deteriorated  into  car-
diogenic  shock  of unknown  etiology.  This  patient  survived  by  IABP  circulatory  support  with alternative
argatroban  anticoagulant  therapy;  and  there  were  no  signs  of  thrombus  or  thromboembolism  in this
patient  or  on the  catheter  itself.  Our  report  suggests  that alternative  anticoagulation  by argatroban  may
be  a safe  and  effective  therapeutic  option  in  seriously  ill patients  requiring  IABP  support  and  nonheparin
2  Jap
anticoagulation.
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Intra-aortic balloon counterpulsation (IABP) is one of the
ost widely used circulatory assist devices today, and has been
mployed as a treatment of last resort for mortally ill patients
uffering from various cardiovascular conditions, including car-
iogenic shock. Because thrombus or thromboembolism can
e IABP-related fatal complications, prophylactic systemic hep-
rinization has been commonly utilized to prevent such thrombotic
omplications during IABP treatment [1]. On the other hand,
eparin-induced thrombocytopenia (HIT) is an immune-mediated
yndrome associated with thrombosis [2]. To date, however, there
s little consensus or few data to support the safety and efﬁcacy of
lternative anticoagulants to heparin for patients with HIT during
ABP management.
We  here report our experience in the management of a patient
ho was diagnosed with HIT type II before and deteriorated into
ardiogenic shock; and the patient survived having been supported
y IABP with alternative argatroban anticoagulant therapy.ase  report
A  47-year-old woman was admitted to our hospital in January
012 with the diagnosis of acute heart failure. One week earlier, she
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had experienced chest discomfort followed by dyspnea on exertion,
easy fatigability, and orthopnea which gradually became worse.
Her past medical history included bronchial asthma, eosinophilia of
unknown etiology, and idiopathic upper limb deep venous throm-
bosis (DVT) with bilateral pulmonary thromboembolism (PTE)
in 2007. At that time, she was treated by oral anticoagulation
therapy with warfarin and intravenous heparin infusion against
DVT/PTE, however, subsequently systemic thrombosis developed.
Serum anti-platelet factor 4/heparin antibody was measured and
proved to be positive; the diagnosis of HIT type II was made. It
was also revealed that she had an allergy to contrast medium.
Immediately after diagnosis of HIT, discontinuing heparin infusion,
warfarin administration was  continued, and ﬁnally she was dis-
charged without any exertional symptoms. Echocardiography at
that time demonstrated normal left ventricular (LV) function with-
out chamber dilatation. She was  followed up with no medication
after cessation of warfarin medication in 2009.
On physical examination at admission, she was  afebrile, and
had rest dyspnea, blood pressure of 90/60 mmHg  and regular pulse
of 120 beats/min. Oxygen saturation on room air was 92%. She
had regular heart sounds and no murmur or gallop, but she had
bilateral inspiratory coarse crackles on the lung. No edema of the
extremities was  observed. Electrocardiogram (ECG) revealed sinus
tachycardia, low voltage in all leads, ST elevation in V1–3 leads, QS
pattern in the V1–4 leads, and slight ST depression in V5–6 leads
(Fig. 1). The ECG pattern was signiﬁcantly different from previous
ECG recorded in 2007. Troponin T was elevated to 0.5220 ng/mL and
brain natriuretic peptide was 1830 pg/mL. Creatine phosphokinase
vier Ltd. All rights reserved.
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Fig. 1. (A) 12-lead electrocardiogram (ECG) in this patient recorded in our hospital in 2007, showing almost normal ECG ﬁndings. In the right panel, we show chest X-ray
at  that time (A′). (B) 12-lead ECG obtained on admission in 2012; sinus tachycardia, signiﬁcant low voltage in all leads, ST elevation in V1–3 leads, QS pattern in the V1–4
leads, and slight ST depression in V5–6 leads were observed. Her chest X-ray revealed hilar and pulmonary edema and blunting of costophrenic angles, suggestive ﬁndings
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as 103 IU/L, and C-reactive protein was 0.73 mg/dL. White blood
ell count was also normal as well as eosinophil count. d-dimer
as elevated to 2.3 g/mL and protein C was slightly decreased to
6%; other hemostatic markers, tumor, or collagen markers were
lmost normal (Table 1). Chest X-ray showed bilateral pulmonary
dema. A transthoracic echocardiogram showed diffuse LV sys-
olic dysfunction with ejection fraction of 24%, low cardiac index of
.5 L/min/m2, dilatation of inferior vena cava, mild mitral regurgi-
ation, and slightly edematous myocardium, but no left ventricular
ilatation.
After admission, she immediately developed cardiogenic shock
ith severe dyspnea and reduced blood pressure. Intravenous
notropes and diuretics were initiated; however, cardiac catheter-
zation including coronary angiography and myocardial biopsy
ould not be employed because of her history of HIT and
llergic reaction to contrast medium. Despite inotropic support
f depressed LV function (dobutamine, dopamine, and nora-
renaline), she experienced hemodynamic deterioration with sinus
achycardia (120–140 beats/min) and hypotension (70/30 mmHg).
n addition, her oxygen saturation level had decreased beyond
0% in spite of oxygen supplementation through a face mask.
n this clinical situation, mechanical circulatory support was
nevitable; we thus decided to start IABP support. We  selectedheparin-nonbonded IABP catheter (Xemex, Zeon Medical, Japan)
and managed anticoagulation with intravenous argatroban: initial
dose of 0.7 g/kg/min (standard initial dose utilized in HIT type II
in Japan) and adjusted to maintain activated partial thromboplas-
tin time (aPTT) between 65 and 90 s (1.5–2 times baseline). Steroid
pulse therapy: methylprednisolone 1 g/day for 3 days was also initi-
ated considering the possibility of eosinophilic myocarditis despite
lack of deﬁnite diagnosis. Several days later, the patient’s grad-
ual recovery of hemodynamic status could lead to the tapering of
inotropes and oxygen supplementation. Systemic steroid therapy
seemed to be effective in the patient, so we continued to admin-
ister oral prednisolone. On the ﬁfth day after insertion, weaning
from IABP could begin by decreasing the balloon augmentation
ratio from 1:1 to 1:2, and IABP support could be withdrawn with-
out hemodynamic deterioration (Fig. 2). Hemostatic parameter of
d-dimer was not signiﬁcantly increasing during IABP management,
and there were no signs of thrombus or thromboembolism in this
patient or on the catheter itself. Oral prednisolone was initiated
at a dose of 30 mg/day and gradually tapered to 20 mg/day. We
also administered medications for chronic heart failure one after
another: angiotensin-converting enzyme inhibitor, -blocker, and
diuretics. Without further events, she was  discharged and followed
up at our outpatients’ clinic.
e156 N. Tabata et al. / Journal of Cardiolo
Table 1
Laboratory data on admission.
Hemogram
WBC  8.9 × 103 L−1, RBC 4.12 × 106 L−1, Hgb 13.1 g/dL, Hct 39.7%, PLT
262  × 103/L
Biochemical examination
Na  140 mEq/L, K 4.2 mEq/L, Cl 105 mEq/L, Ca 8.9 mg/dL, IP 3.9 mg/dL,
Mg  2.2 mg/dL
BUN  16.0 mg/dL, Crea 0.78 mg/dL, eGFR 62, TP 6.3 g/dL, Alb 3.7 g/dL
CK 103 IU/L, CK-MB 12 IU/L, BNP 1830 g/mL, hs-TnT 0.5220 ng/mL
CRP 0.73 mg/dL, PCT 0.05 ng/mL
TG  78 mg/dL, HDL72 mg/dL, LDL 95 mg/dL, Glu 135 mg/dL, HbA1c(JDS)
4.8%
TSH 4.11 IU/mL, FT3 1.84 pg/mL, FT4 1.19 ng/dL
Hemostatic markers
d-dimer  2.3 g/mL, protein C56%, protein S 74%
Collagen  markers
ANA7  index ds-DNA<0.5 IU/mL, RNP<0.5 U/mL, Sm<0.5 U/mL, SS-A
<0.5  U/mL, SS-B <0.5 U/mL, Scl-70 <0.5 U/mL, Jo-1 <0.5 U/mL, CENP-B
<0.5 U/mL, CLB2GP1 <1.3 U/mL, lupus anticoagulant 1.04, PR3-ANCA
<10EU, MPO-ANCA <10EU
Tumor  markers
CEA  1.3 ng/mL, CA19-9 0.6 U/mL, CA125 21.9 U/mL, SCC 0.9 ng/mL,
CYFRA 0.6 ng/mL
Abbreviations: WBC, white blood cells; RBC, red blood cells; Hgb, hemoglobin; Hct,
hematocrit; PLT, platelets; Na, natrium; K, kalium; Cl, chloride; Ca, calcium; IP,
inorganic phosphorus; Mg,  magnesium; BUN, blood urea nitrogen; Crea, creati-
nine; eGFR, estimated glomerular ﬁltration rate; TP, total protein; Alb, albumin;
CK,  creatine kinase; CK-MB, creatine kinase muscle-brain fraction; BNP, brain
natriuretic  peptide; hs-TnT, high-sensitivity troponin T; CRP, C-reactive protein;
PCT,  procalcitonin; TG, triglyceride; HDL, high-density lipoprotein cholesterol; LDL,
low-density lipoprotein cholesterol; Glu, glucose; HbA1c, hemoglobin A1c; JDS,
Japan Diabetes Society; TSH, thyroid-stimulating hormone; FT3, free T3; FT4, free
T4; ANA, anti-nuclear antibody; ds-DNA, double-stranded deoxyribonucleic acid;
RNP, anti-ribonucleoprotein antibody; Sm, anti-smith antibody; SS-A, anti-SS-A
antibody;  SS-B, anti-SS-B antibody; Scl, anti-scleroderma 70 antibody; CENP-B,
anti-centromere  protein B antibody; CLB2GP1, anti-cardiolipin and anti-beta 2
glycoprotein 1 antibody; PR3-ANCA, proteinase 3-antineutrophil cytoplasmic anti-
body; MPO-ANCA, myeloperoxidase-antineutrophil cytoplasmic antibody; CEA,
carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; CA125, cancer anti-
gen 125; SCC, squamous cell carcinoma antigen; CYFRA, cytokeratin 19 fragment.
Fig. 2. Clinical course after admission to our hospital. She immediately deteriorated into
another.  On the fourth day, intra-aortic balloon counterpulsation (IABP) was  inserted, and s
inotrope support could be gradually tapered, and on the eighth day, IABP was  removed. h
CI,  cardiac index.gy Cases 6 (2012) e154–e157
Discussion
IABP has been widely used in various cardiovascular conditions,
ranging from hemodynamic stabilization in patients with acute
myocardial infarction, high-risk patients undergoing angioplasty or
coronary artery bypass grafting, to patients with cardiogenic shock
[1]. Among complications during IABP, although limb ischemia was
reported to be the most frequent [3], IABP is an intravascular for-
eign body which can stimulate the coagulation system, leading to
thrombus formation. Systemic heparinization during IABP is com-
monly used to prevent such thrombotic complications in many
medical institutions throughout the world.
HIT is a well-recognized complication of heparin therapy
characterized by the formation of antibodies against the heparin-
platelet factor 4 complex and is associated with a high risk of
thrombotic complications [2]. Primary therapy for HIT involves dis-
continuation of heparin, including heparin-bonded catheters and
heparin ﬂushes, and the use of an alternative anticoagulant when
anticoagulation is still necessary [4]. There are a number of alter-
native anticoagulants to heparin in patients with HIT: lepirudin,
bivalirudin, argatroban, fondaparinux, or danaparoid [5]. Among
those candidates, only argatroban is available in Japan.
Argatroban is a direct thrombin inhibitor, which binds selec-
tively and reversibly to thrombin and inhibits thrombin-catalyzed
reactions. It has a short half-life of 24 min; its effect is monitored
by aPTT, steady anticoagulation is achieved one to three hours after
intravenous initiation, and after discontinuation, the aPTT returns
to normal within two  hours [6]. This shorter and reversible throm-
bin inhibition may  be an advantage in some situations, such as the
need for rapid reversal of anticoagulation because of bleeding. A
prior clinical trial evaluated the efﬁcacy and safety of argatroban in
patients with HIT in reducing subsequent thrombotic events with-
out increasing bleeding rates [7]. Another study reported that this
agent had been successfully employed in patients with a history
of HIT needing acute anticoagulation with no major bleeding, new
thromboembolic events, or other adverse effects [8].
 cardiogenic shock, and we initiated intravenous inotropes and diuretics one after
ystemic steroid therapy was also initiated. As the hemodynamic state got stabilized,
ANP, human atrial natriuretic peptide; sBP, systolic blood pressure; HR, heart rate;
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Our patient rapidly deteriorated into cardiogenic shock. This
as a classical presentation of fulminant myocarditis, but we could
ot make a deﬁnite diagnosis because of allergy to contrast medium
nd a history of HIT. In this case, the use of IABP was  a challenge
or us because this patient seemed to have a thrombotic tendency,
o alternative anticoagulation to heparin was needed. In addition,
here is little consensus or few data to support the safety of alter-
ative anticoagulation during IABP, to our knowledge. However,
rgatroban has proved to be available for patients with HIT; and
ased on its mechanism of action we could postulate that it would
anifest an anticoagulation effect in the patient with IABP. So we
ecided to utilize this agent for systemic anticoagulation, and could
uccessfully manage IABP mechanical support.
Recently, it has been questioned whether heparinization is nec-
ssary in patients who have an IABP [9], because it might increase
he risk of bleeding as a side effect. However, like our patient,
here are some cases in which we need anticoagulation, for exam-
le because of thrombotic tendency. Moreover, we  had to select
eparin-nonbonded IABP and it was reported that thrombus was
igniﬁcantly detected at the insertion site, on the catheter itself,
nd in the distal femoral artery in cases with heparin-nonbonded
ABP [10].
onclusion
We  report one case in which we could successfully manage IABP
mploying anticoagulation with argatroban. Our report suggests
hat alternative anticoagulation with argatroban may  be safe and
ffective in seriously ill patients requiring IABP support and non-
eparin anticoagulation, although further clinical investigations
re necessary to conﬁrm that.isclosures
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